Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures

Journal: Nature Communications

Published: 2020-05-14

DOI: 10.1038/s41467-020-16212-w

Affiliations: 10

Authors: 18

Go to article
Institutions Share
Department of Cancer Physiology, MOFFITT, United States of America (USA) 0.28
Department of Translational Hematology and Oncology Research (THOR), Cleveland Clinic, United States of America (USA) 0.28
Department of Biostatistics and Bioinformatics, MOFFITT, United States of America (USA) 0.11
Department of Molecular Medicine, USF, United States of America (USA) 0.06
School of Medicine, CWRU, United States of America (USA) 0.06
Nalecz Institute of Biocybernetics and Biomedical Engineering (IBIB), PAS, Poland 0.06
Department of Pathology, MOFFITT, United States of America (USA) 0.06
Department of Thoracic Oncology, MOFFITT, United States of America (USA) 0.06
Supercomputing and Bioinnovation Center (SCBI), UMA, Spain 0.03
University of South Florida (USF), United States of America (USA) 0.03

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER